0001666071-24-000027.txt : 20240305
0001666071-24-000027.hdr.sgml : 20240305
20240305162401
ACCESSION NUMBER: 0001666071-24-000027
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240301
FILED AS OF DATE: 20240305
DATE AS OF CHANGE: 20240305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Temsamani Karim Saad
CENTRAL INDEX KEY: 0001944491
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38386
FILM NUMBER: 24720849
MAIL ADDRESS:
STREET 1: C/O CARDLYTICS, INC.
STREET 2: 675 PONCE DE LEON AVENUE NE, SUITE 6000
CITY: ATLANTA
STATE: GA
ZIP: 30308
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cardlytics, Inc.
CENTRAL INDEX KEY: 0001666071
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROGRAMMING, DATA PROCESSING, ETC. [7370]
ORGANIZATION NAME: 06 Technology
IRS NUMBER: 263039436
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 675 PONCE DE LEON AVENUE, NE
STREET 2: SUITE 4100
CITY: ATLANTA
STATE: GA
ZIP: 30308
BUSINESS PHONE: 888-798-5802
MAIL ADDRESS:
STREET 1: 675 PONCE DE LEON AVENUE, NE
STREET 2: SUITE 4100
CITY: ATLANTA
STATE: GA
ZIP: 30308
4
1
wk-form4_1709673820.xml
FORM 4
X0508
4
2024-03-01
0
0001666071
Cardlytics, Inc.
CDLX
0001944491
Temsamani Karim Saad
675 PONCE DE LEON AVE. NE
SUITE 4100
ATLANTA
GA
30308
1
1
0
0
Chief Executive Officer
0
Common Stock
2024-03-01
4
M
0
84078
A
361813
D
Common Stock
2024-03-04
4
S
0
34515
7.89
D
327298
D
Restricted Stock Unit
2024-03-01
4
M
0
84078
0
D
Common Stock
84078
840789
D
Each RSU represents a contingent right to receive one share of common stock of the Issuer, or at the election of the Issuer, its cash equivalent.
Shares were sold solely to satisfy withholding tax obligations that resulted from the delivery of shares of common stock for RSUs that vested on March 1, 2024. The Reporting Person did not sell shares for any other purpose.
The price reported is a weighted average sales price. These shares were sold in multiple transactions at prices ranging from $7.66 to $8.405, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3).
25% of the RSUs vested on September 1, 2023, with the remaining 75% having vested or vesting in equal amounts over the subsequent three years quarterly thereafter, provided that the Reporting Person remains employed by the Issuer on such vesting date.
/s/ Nick Lynton, Attorney-in-Fact
2024-03-05